RT Journal Article
SR Electronic
T1 Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition and brain volume
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.09.20209833
DO 10.1101/2020.10.09.20209833
A1 Salzmann, Antoine
A1 James, Sarah-Naomi
A1 Williams, Dylan M.
A1 Richards, Marcus
A1 Cadar, Dorina
A1 Schott, Jonathan M.
A1 Coath, William
A1 Sudre, Carole H.
A1 Chaturvedi, Nishi
A1 Garfield, Victoria
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.09.20209833.abstract
AB Background The insulin/insulin-like signalling (IIS) pathways, including Insulin-like Growth Factors (IGFs), varies with age. However, their association with late-life cognition and neuroimaging parameters is not well characterised.Methods Using data from the British 1946 birth cohort we investigated associations of IGF-I, -II and IGFBP-3 (measured at 53 and 60-64 years) with cognitive performance (word learning test (WLT) and visual letter search (VLS) – at 60-64y and 69y) and cognitive state (Addenbrooke’s Cognitive Exam-III (ACE-III) - at 69-71y), and in a proportion, quantified neuroimaging measures (whole brain volume (WBV); white matter hyperintensity volume (WMHV); hippocampal volume (HV)). Regression models included adjustments for demographic, lifestyle and health factors.Results Higher IGF-I and IGF-II at 53y was associated with higher ACE-III scores (ß 0.07 95%CI [0.02,0.12]; scoreACE-III 89.48 [88.86,90.1], respectively). IGF-II at age 53y was additionally associated with higher WLT scores (scoreWLT 20 [19.35,20.65]). IGFBP-3 at 60-64y was associated with favourable VLS score at 60-64y and 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.02,0.12], respectively), higher memory and cognitive state at 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.01,0.13], respectively) and reduced WMHV (ß −0.1, [-0.21,-0.00]). IGF-I/IGFBP-3 at 60-64y was associated with slower VLS scores at 69y (ß −0.08, [-0.15,-0.02]).Conclusions Increased measure in IIS parameters (IGF-I, -II and IGFBP-3) relate to better cognitive state in later life. Furthermore, there were apparent associations with specific cognitive domains (IGF-II relating to memory; IGFBP-3 to memory, processing speed and WMHV; and IGF-I/IGFBP-3 molar ratio with slower processing speed). IGFs and IGFBP-3 are associated with favourable cognitive function outcomes.Competing Interest StatementJMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, and Eli Lilly, given educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. NC receives funds for serving on a Data Safety Monitoring Committee for a study sponsored by AstraZeneca. All other authors have no conflicts of interest to declare.Funding StatementThis work was supported by the UK Medical Research Council, which provides core funding for the MRC Unit For Lifelong Health and Ageing at UCL and the MRC National Survey of Health and Development (MC_UU_00019/1) and supports AS, NC, DW, MR, SNJ (MC_ST_LHA_2019; MC_UU_0019/2, MC_UU_0019/3). Insight 46 is principally funded by grants from Alzheimer's Research UK (and SNJ ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575) and The Drake Foundation. JMS acknowledges the EPSRC (EP/J020990/1) and European Union's Horizon 2020 research and innovation programme (Grant 666992) and a Weston Brain Institute and Selfridges Group Foundation award (176724). DC is funded by the National Institute on Aging (RO1AG017644) and ESRC (ES/S013830/1). CHS is supported by an Alzheimer's Society Junior Fellowship (AS-JF-17-011). VG is funded by Joint Diabetes UK and British Heart Foundation (15/0005250).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MRCAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to relevant data available upon application to the NSHD data sharing committee.